<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Ital J Pediatr</journal-id>
      <journal-id journal-id-type="iso-abbrev">Ital J Pediatr</journal-id>
      <journal-title-group>
        <journal-title>Italian Journal of Pediatrics</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1824-7288</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25255796</article-id>
      <article-id pub-id-type="pmc">4422474</article-id>
      <article-id pub-id-type="publisher-id">78</article-id>
      <article-id pub-id-type="doi">10.1186/s13052-014-0078-2</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Hydrocortisone malabsorption due to polyethylene glycols (Macrogol 3350) in a girl with congenital adrenal insufficiency</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Stagi</surname>
            <given-names>Stefano</given-names>
          </name>
          <address>
            <email>stefano.stagi@yahoo.it</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Del Greco</surname>
            <given-names>Paolo</given-names>
          </name>
          <address>
            <email>paolodelgreco@yahoo.it</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ricci</surname>
            <given-names>Franco</given-names>
          </name>
          <address>
            <email>frank8622@hotmail.it</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Iurato</surname>
            <given-names>Chiara</given-names>
          </name>
          <address>
            <email>chiara.iurato@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Poggi</surname>
            <given-names>Giovanni</given-names>
          </name>
          <address>
            <email>giovanni.poggi@meyer.it</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Seminara</surname>
            <given-names>Salvatore</given-names>
          </name>
          <address>
            <email>seminara@unifi.it</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>de Martino</surname>
            <given-names>Maurizio</given-names>
          </name>
          <address>
            <email>maurizio.demartino@unifi.it</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <aff id="Aff1">Department of Health Sciences, University of Florence, Anna Meyer Children&#x2019;s University Hospital, Florence, Italy </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>26</day>
        <month>9</month>
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2014</year>
      </pub-date>
      <volume>40</volume>
      <elocation-id>78</elocation-id>
      <history>
        <date date-type="received">
          <day>9</day>
          <month>6</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>4</day>
          <month>9</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Stagi et al.; licensee BioMed Central Ltd. 2014</copyright-statement>
        <license license-type="open-access">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Background</title>
          <p>Primary adrenal insufficiency is relatively rare in children and, if unrecognized, may present with cardiovascular collapse, making it a potentially life-threatening entity.</p>
        </sec>
        <sec>
          <title>Case presentation</title>
          <p>The proposita, 11&#xA0;months old of age, was admitted for lethargy and severe dehydration. Blood pressure was 62/38&#xA0;mm Hg, and biochemical measurements showed hyponatraemia, hypochloraemia, hyperkalaemia, and metabolic acidaemia. Renin activity was 1484 &#x3BC;U/mL; cortisol, 1.03&#xA0;&#x3BC;g/dL (normal, 5-25&#xA0;&#x3BC;g/dL); and corticotropin (ACTH), 4832&#xA0;ng/L (normal, 9-52&#xA0;ng/L). Adrenal deficiency was diagnosed, and replacement therapy with glucocorticoids and mineralocorticoids was initiated. After 40&#xA0;days, ACTH was 797&#xA0;ng/L.</p>
          <p>During follow-up, the patient started taking macrogol twice daily for constipation and experienced a significant increase in ACTH (3262&#xA0;ng/L), which dropped to 648&#xA0;ng/L when macrogol was stopped. After arbitrary reintroduction of macrogol, the child presented with hypoglycaemia, lethargy, weakness, and hypotonia; ACTH was 3145&#xA0;ng/L. After again stopping macrogol, her ACTH was near normalized (323&#xA0;ng/L).</p>
        </sec>
        <sec>
          <title>Conclusion</title>
          <p>Hydrocortisone malabsorption may be caused by macrogol use. Because chronic constipation is frequently reported in children, the possibility that macrogol contributes to adrenal crisis should be taken in account.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Macrogol</kwd>
        <kwd>Hydrocortisone</kwd>
        <kwd>Adrenal insufficiency</kwd>
        <kwd>Malabsorption</kwd>
        <kwd>Polyethylene glycol</kwd>
        <kwd>Constipation</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2014</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1" sec-type="introduction">
      <title>Introduction</title>
      <p>Adrenal insufficiency is relatively rare in children and may be categorized as primary or secondary and congenital or acquired [<xref ref-type="bibr" rid="CR1">1</xref>]. Primary adrenal insufficiency can be caused by a deficiency in steroid biosynthesis or abnormal adrenal gland development. It is a life-threatening disorder that can result from primary adrenal failure or secondary adrenal disease resulting in impairment of the hypothalamic-pituitary axis. Prompt diagnosis and urgent mineralocorticoid and glucocorticoid replacement is mandatory [<xref ref-type="bibr" rid="CR2">2</xref>]; however, correct management is also essential [<xref ref-type="bibr" rid="CR3">3</xref>].</p>
      <p>Chronic idiopathic constipation is frequently reported and reduces patient quality of life [<xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR5">5</xref>]. In fact, chronic constipation is associated with long-term problems including megarectum, reduced sensitivity of the rectum to the presence of faeces, and abnormal gut motility [<xref ref-type="bibr" rid="CR4">4</xref>]. In many children, constipation is triggered by painful bowel movements caused by factors such as toilet training, changes in routine or diet, stressful events, intercurrent illness, or delaying defecation [<xref ref-type="bibr" rid="CR4">4</xref>]. Therefore, managing chronic constipation in children effectively and early in its course is important in preventing long-term defecation disorders [<xref ref-type="bibr" rid="CR4">4</xref>].</p>
      <p>Polyethylene glycols (PEGs, or macrogols) are hydrophilic polymers of ethylene oxide [<xref ref-type="bibr" rid="CR6">6</xref>] used in many drugs such as bowel preparations, dispersing agents, and excipients, and in cosmetics [<xref ref-type="bibr" rid="CR7">7</xref>]. Water makes up 75-80% (wt/wt) of the normal stool, and a difference of only 10% in hydration results in marked changes in stool consistency [<xref ref-type="bibr" rid="CR8">8</xref>]. Because PEG is a large molecular weight water-soluble polymer, it has the capacity to form hydrogen bonds with 100 molecules of water per molecule of PEG [<xref ref-type="bibr" rid="CR9">9</xref>]. When PEG is administered orally, the resulting hydration of the colonic content facilitates transit and painless defecation in a linear dose-dependent fashion [<xref ref-type="bibr" rid="CR10">10</xref>]. Therefore, PEG-based laxatives, when used in escalating doses, can also be used to completely remove faecal loading in preference to rectally-administered treatments. Standard management of chronic constipation tends to begin with correction of dietary and lifestyle factors that predispose to the condition and focus on increasing dietary fibre and fluid intake [<xref ref-type="bibr" rid="CR11">11</xref>]. Dietary manipulation alone, including the use of corn syrup, was successful in resolving all symptoms of constipation in 25% of children aged up to 2&#xA0;years in one US study [<xref ref-type="bibr" rid="CR5">5</xref>].</p>
      <p>We describe a girl with adrenal insufficiency managed with hydrocortisone and fluorocortisone who showed an adrenal crisis after administration of macrogol 3350, and we discuss this aspect, focusing on the aetiology of adrenal insufficiency in childhood.</p>
    </sec>
    <sec id="Sec2">
      <title>Case report</title>
      <p>The proposita, 11&#xA0;months old of age, was admitted to Anna Meyer Children&#x2019;s University Hospital for lethargy and severe dehydration without history of vomiting or diarrhoea. She was the first child of non-consanguineous, young, healthy Italian parents, born at term (39 wks of gestation) by natural childbirth. Birth weight was 3200&#xA0;g (0.12 standard deviation score [SDS], 50<sup>th</sup>-75<sup>th</sup> centile), length, 51&#xA0;cm (1.12 SDS, 75<sup>th</sup>-90<sup>th</sup> centile), and head circumference, 35&#xA0;cm (1.04 SDS, 75<sup>th</sup>-90<sup>th</sup> centile). There were no perinatal problems or familial history of similar presentations or features of endocrine disease. Neuromotor development was normal; she was sitting at 5&#xA0;months.</p>
      <p>At 10&#xA0;months, 20&#xA0;days of age, she started showing weight loss, lethargy, weakness, hypotonia, and dark skin. She was mildly dehydrated. Her body weight, length, and head circumference were 10.850&#xA0;kg (1.89 SDS, 97<sup>th</sup> centile), 73&#xA0;cm (0.61 SDS, 50<sup>th</sup>-75<sup>th</sup> centile), and 46.5&#xA0;cm (1.30 SDS, 90<sup>th</sup> centile), respectively. There were no dysmorphic features. External genitalia were normal female type with no ambiguity. There was no abdominal or inguinal mass discovered upon abdominal examination. Blood pressure was 62/38&#xA0;mm Hg; respiration, 35/min; pulse, 121/min; and body temperature, 37.3&#xB0;C.</p>
      <p>Biochemical measurements indicated hyponatraemia (Na, 125&#xA0;mEq/L), hypochloraemia (Cl, 86&#xA0;mEq/L), hyperkalaemia (K, 5.7&#xA0;mEq/L), metabolic acidaemia by arterial venous blood gas, elevated serum urea nitrogen (60&#xA0;mg/dL), and normal creatinine (0.3&#xA0;mg/dL). Glucose was 56&#xA0;mg/dL (normal, 55-110&#xA0;mg/dL). An extensive endocrine work-up, carried out at 8&#x2009;<sc>am</sc> after an overnight fast, showed free thyroxin was 1.27&#xA0;ng/dL (normal, 0.80-1.90&#xA0;ng/dL); thyrotropin, 3.96 &#x3BC;IU/dL (normal, 0.4-4.0 &#x3BC;IU/dL); aldosterone, 0.19&#xA0;nmol/L (normal, 0.96-8.31&#xA0;nmol/L); renin activity, 1484 &#x3BC;U/mL per h (normal, 2-10.2 &#x3BC;U/mL per h); 17-OH-progesterone, &lt; 0.5&#xA0;nmol/L; dehydroepiandrosterone sulfate, &lt; 15&#xA0;&#x3BC;g/dL; cortisol, 1.03&#xA0;&#x3BC;g/dL (normal, 5-25&#xA0;&#x3BC;g/dL); ACTH, 4832&#xA0;ng/L (normal, 9-52&#xA0;ng/L; Figure&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>), luteinizing hormone, 2.3&#xA0;IU/L; and follicle stimulating hormone, 5.6&#xA0;IU/L.<fig id="Fig1"><label>Figure 1</label><caption><p>
<bold>MRI scan of the bilateral adrenal glands revealing agenesis of the right (A) and hypoplasia of the left (B) adrenal glands.</bold>
</p></caption><graphic xlink:href="13052_2014_78_Fig1_HTML" id="MO1"/></fig></p>
      <p>Serum cortisol and plasma ACTH levels were measured routinely using an Immulite 2000 chemiluminescence immunometric assay (Diagnostic Products Corporation, xLos Angeles, CA, USA). The cortisol inter-assay and intra-assay coefficients of variation were&#x2009;&lt;&#x2009;9.5% and 7.4%, respectively. The ACTH inter-assay and intra-assay coefficients of variation ranged from 6.1% to 10.0% and from 6.7% to 9.5%, respectively.</p>
      <p>The patient was hydrated with normal saline and required vasopressors. Adrenal deficiency was diagnosed considering the hyponatraemia, hyperkalaemia, metabolic acidaemia, and cortisol and corticotropin levels.</p>
      <p>The usual causes of primary adrenal insufficiency were ruled out (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>). Family history was negative for autoimmune diseases and endocrinological or genetic syndromes. Renal Doppler ultrasonography was performed and was normal. Autoimmune Addison, in the context of autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED) or other autoimmune syndromes was ruled out by clinical and biochemical evaluation. Mantoux was negative and Veneral Disease Research Laboratory (VDRL) was non-reactive. Human immunodeficiency virus was seronegative. Plasma levels of very long chain fatty acids (VLCFAs) were normal. We performed a synthetic ACTH stimulation test intravenously at 8&#x2009;<sc>am</sc> after an overnight fast, and the cortisol response, measured at 0, 30, and 60&#xA0;minutes after infusion was blunted (0.98, 1.39, and 2.01&#xA0;&#x3BC;g/dL, respectively). An MRI scan of the bilateral adrenal glands revealed agenesis of the right and hypoplasia of the left adrenal glands (Figures&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>A and B).<table-wrap id="Tab1"><label>Table 1</label><caption><p>
<bold>Typical causes of primary adrenal insufficiency</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th>
<bold>1) Genetic disorders</bold>
</th><th>
<bold>OMIM</bold>
<sup><bold>1</bold></sup>
<bold>(gene map)</bold>
</th><th>
<bold>Etiologic mechanisms</bold>
</th><th>
<bold>Other signs and symptoms</bold>
</th></tr></thead><tbody><tr valign="top"><td>&#x2003;Adrenoleukodystrophy</td><td>300100 (Xq28)</td><td>Mutations of <italic>ABCD1</italic>
<sup>2</sup>, <italic>ABCD2</italic>
<sup>3</sup>
</td><td>Weakness, diminished visual acuity, deafness, cerebellar ataxia, hemiplegia, convulsions, dementia</td></tr><tr valign="top"><td>&#x2003;Congenital adrenal hyperplasia</td><td/><td/><td/></tr><tr valign="top"><td>&#x2003;&#x2003;
<italic>21</italic>-hydroxylase deficiency</td><td>201910 (6p21.33)</td><td>Mutations of <italic>CYP21A2</italic>
<sup>4</sup>
</td><td>Hyperandrogenism, ambiguous genitalia in females</td></tr><tr valign="top"><td>&#x2003;&#x2003;
<italic>11&#x3B2;</italic>-hydroxylase deficiency</td><td>202010 (8q24.3)</td><td>Mutations of <italic>CYP11B1</italic>
<sup>5</sup>
</td><td>Hyperandrogenism, hypertension</td></tr><tr valign="top"><td>&#x2003;&#x2003;
<italic>3&#x3B2;</italic>-hydroxysteroid dehydrogenase type 2 deficiency</td><td>201810 (1p12)</td><td>Mutations of <italic>HSD3B2</italic>
<sup>6</sup>
</td><td>Ambiguous genitalia in boys, postnatal virilisation in girls</td></tr><tr valign="top"><td>&#x2003;&#x2003;
<italic>17&#x3B1;</italic>-hydroxylase deficiency</td><td>202110 (10q24.32)</td><td>Mutations of <italic>CYP17A1</italic>
<sup><italic>7</italic></sup>
</td><td>Pubertal delay in both sexes, primary amenorrhea, lack of secondary sexual characteristics, hypertension</td></tr><tr valign="top"><td>&#x2003;&#x2003;P450 oxidoreductase deficiency</td><td>201750 (7q11.23)</td><td>Mutations of <italic>POR</italic>
<sup>8</sup>
</td><td>Skeletal malformations, especially craniofacial; severe abnormal genitalia</td></tr><tr valign="top"><td>&#x2003;&#x2003;P450 side-chain cleavage deficiency</td><td>613743 (15q24.1)</td><td>Mutations of <italic>CYP11A1</italic>
<sup>9</sup>
</td><td>XY sex reversal</td></tr><tr valign="top"><td>&#x2003;&#x2003;Congenital lipoid adrenal hyperplasia</td><td>201710 (8p11.23)</td><td>Mutations of <italic>STAR</italic>
<sup>10</sup>
</td><td>XY sex reversal</td></tr><tr valign="top"><td>&#x2003;Smith-Lemli-Opitz syndrome</td><td>270400 (11q13.4)</td><td>Mutations of <italic>DHCR7</italic>
<sup>11</sup>
</td><td>Mental retardation, craniofacial malformations, growth failure, cholesterol deficiency</td></tr><tr valign="top"><td>&#x2003;Adrenal hypoplasia congenita</td><td/><td/><td/></tr><tr valign="top"><td>&#x2003;&#x2003;X-linked</td><td>300200 (Xp21.2)</td><td>Mutations of <italic>NR0B1</italic>
<sup>12</sup>
</td><td>Hypogonadotropic hypogonadism in boys (occasionally in carrier females for skewed X-chromosome inactivation)</td></tr><tr valign="top"><td>&#x2003;&#x2003;Xp21 deletion syndrome</td><td>300679 (Xp21)</td><td>Deletion of <italic>GK</italic>
<sup>13</sup>, <italic>DMD</italic>
<sup>14</sup>, and <italic>NR0B1</italic>
</td><td>Duchenne muscular dystrophy, glycerol kinase deficiency psychomotor retardation</td></tr><tr valign="top"><td>&#x2003;&#x2003;
<italic>SF1</italic>-linked</td><td>612965 (9q33.3)</td><td>Mutations of <italic>NR5A1</italic>
<sup>15</sup>
</td><td>XY sex reversal</td></tr><tr valign="top"><td>&#x2003;IMAGe syndrome</td><td>614732 (11p15.4)</td><td>Mutations of <italic>CDKN1C</italic>
<sup>16</sup>
</td><td>Intrauterine growth retardation, metaphyseal dysplasia, genital abnormalities</td></tr><tr valign="top"><td>&#x2003;Kearns-Sayre syndrome</td><td/><td>Deletions of mitochondrial DNA</td><td>Deafness; heart, ocular and cerebral involvement; skeletal muscle myopathy; intestinal disorders; hormonal deficits</td></tr><tr valign="top"><td>&#x2003;Wolman disease</td><td>278000 (10q23.31)</td><td>Mutations of <italic>LIPA</italic>
<sup>17</sup>
</td><td>Bilateral adrenal calcification, hepatosplenomegaly</td></tr><tr valign="top"><td>&#x2003;Sitosterolaemia</td><td/><td>Mutations of <italic>ABCG5</italic>
<sup><italic>18</italic></sup> and <italic>ABCG8</italic>
<sup>19</sup>
</td><td>Xanthomata, arthritis, premature coronary artery disease, short stature, gonadal failure</td></tr><tr valign="top"><td>&#x2003;Familial glucocorticoid deficiency or corticotropin insensitivity syndromes</td><td/><td/><td/></tr><tr valign="top"><td>&#x2003;&#x2003;Type 1</td><td>202200 (18p11.21)</td><td>Mutations of <italic>MC2R</italic>
<sup>20</sup>
</td><td>Hyperpigmentation, tall stature, typical facial features, lethargy and muscle weakness with normal blood pressure</td></tr><tr valign="top"><td>&#x2003;&#x2003;Type 2</td><td>607398 (21q22.11)</td><td>Mutations of <italic>MRAP</italic>
<sup>21</sup>
</td><td>Hyperpigmentation, normal height, hypoglycaemia, lethargy, and muscle weakness with normal blood pressure</td></tr><tr valign="top"><td>&#x2003;&#x2003;Variant of familial glucocorticoid deficiency</td><td>609981 (8q11.21)</td><td>Mutations of <italic>MCM4</italic>
<sup>22</sup>
</td><td>Growth failure, increased chromosomal breakage, natural killer cell deficiency</td></tr><tr valign="top"><td>&#x2003;Primary generalised glucocorticoid resistance</td><td>(5q31.3)</td><td>Mutations of <italic>GCCR</italic>
<sup>23</sup>
</td><td>Fatigue, hypoglycaemia, hypertension, hyperandrogenism</td></tr><tr valign="top"><td>&#x2003;Triple A syndrome (Allgrove&#x2019;s syndrome)</td><td>231550 (12q13.13)</td><td>Mutations of <italic>AAAS</italic>
<sup><italic>24</italic></sup>
</td><td>Achalasia, alacrima, deafness, mental retardation, hyperkeratosis</td></tr><tr valign="top"><td>
<bold>2) Acquired diseases</bold>
</td><td/><td/><td/></tr><tr valign="top"><td>&#x2003;Bilateral adrenal haemorrhage</td><td align="center">-</td><td>Meningococcal sepsis, antiphospholipid syndrome</td><td>Symptoms and signs of underlying disease</td></tr><tr valign="top"><td>&#x2003;Bilateral adrenal metastases</td><td align="center">-</td><td>Lung, stomach, breast, and colon cancers</td><td>Disease-associated clinical manifestations</td></tr><tr valign="top"><td>&#x2003;Bilateral adrenalectomy</td><td align="center">-</td><td>Adrenal masses, phaeochromocytoma unresolved Cushing&#x2019;s syndrome</td><td>Symptoms and signs of underlying disease</td></tr><tr valign="top"><td>&#x2003;Bilateral adrenal infiltration</td><td align="center">-</td><td>Adrenal lymphoma, amyloidosis, haemochromatosis</td><td>Disease-associated clinical manifestations</td></tr><tr valign="top"><td>&#x2003;Drug-induced adrenal insufficiency</td><td align="center">-</td><td>Anticoagulants, ketoconazole, fluconazole, etomidate, phenobarbital, phenytoin, rifampicin, troglitazone</td><td>None, unless related to drug</td></tr><tr valign="top"><td>&#x2003;Infectious adrenalitis</td><td align="center">-</td><td>Tuberculosis, HIV-1, histoplasmosis, cryptococcosis, coccidioidomycosis, syphilis, trypanosomiasis</td><td>Disease-associated manifestations in other organs</td></tr><tr valign="top"><td>&#x2003;Autoimmune adrenalitis</td><td align="center">-</td><td/><td/></tr><tr valign="top"><td>&#x2003;&#x2003;Isolated</td><td/><td/><td>None</td></tr><tr valign="top"><td>&#x2003;&#x2003;APS type 1 (APECED)</td><td>240300 (21q22.3)</td><td>Mutations of <italic>AIRE</italic>
<sup>25</sup>
</td><td>Chronic mucocutaneous candidosis, hypoparathyroidism, other autoimmune diseases</td></tr><tr valign="top"><td>&#x2003;&#x2003;APS type 2</td><td>269200</td><td/><td>Thyroid autoimmune disease, type 1 diabetes, other autoimmune diseases</td></tr><tr valign="top"><td>&#x2003;&#x2003;APS type 4</td><td/><td/><td>Autoimmune gastritis, vitiligo, coeliac disease, alopecia, excluding thyroid disease and type 1 diabetes</td></tr></tbody></table><table-wrap-foot><p>Modified by Charmandari et al., 2014 [<xref ref-type="bibr" rid="CR16">16</xref>]: <sup>1</sup>OMIM: Online Mendelian Inheritance in Man database; <sup>2</sup>
<italic>ABCD1</italic>: <italic>atp-binding cassette subfamily D, member 1</italic>; <sup>3</sup>
<italic>ABCD2</italic>: <italic>atp-binding cassette, subfamily D, member 2</italic>; <sup>4</sup>
<italic>CYP21A2</italic>: <italic>cytochrome P450, family 21, subfamily A, polypeptide 2</italic>; <sup>5</sup>
<italic>CYP11B1</italic>: <italic>cytochrome P450, subfamily XIB, polypeptide 1</italic>; <sup>6</sup>
<italic>HSD3B2</italic>: <italic>3-beta-hydroxysteroid dehydrogenase 2</italic>; <sup>7</sup>
<italic>CYP17A1</italic>: <italic>cytochrome P450, family 17, subfamily A, polypeptide 1</italic>; <sup>8</sup>
<italic>POR</italic>: <italic>cytochrome P450 oxidoreductase</italic>; <sup>9</sup>
<italic>CYP11A1</italic>: <italic>cytochrome P450, subfamily XIA, polypeptide 1</italic>; <sup>10</sup>
<italic>STAR</italic>: <italic>steroidogenic acute regulatory protein</italic>; <sup>11</sup>
<italic>DHCR7</italic>: <italic>7-dehydrocholesterol reductase</italic>; <sup>12</sup>
<italic>NR0B1</italic>: <italic>nuclear receptor subfamily 0, group B, member 1</italic>; <sup>13</sup>
<italic>GK</italic>: <italic>glycerol kinase</italic>; <sup>14</sup>
<italic>DMD</italic>: <italic>dystrophin</italic>; <sup>15</sup>
<italic>NR5A1</italic>: <italic>nuclear receptor subfamily 5, group A, member 1;</italic>
<sup>16</sup>
<italic>CDKN1C</italic>: <italic>cyclin-dependent kinase inhibitor 1C</italic>; <sup>17</sup>
<italic>LIPA</italic>: <italic>lipase A, lysosomal acid</italic>; <sup>20</sup>
<italic>MC2R</italic>: <italic>melanocortin 2 receptor</italic>; <sup>21</sup>
<italic>MRAP</italic>: <italic>melanocortin 2 receptor accessory protein</italic>; <sup>22</sup>
<italic>MCM4</italic>: <italic>minichromosome maintenance, Saccharomyces Cerevisiae, homolog of, 4;</italic>
<sup>23</sup>
<italic>GCCR</italic>: <italic>glucocorticoid receptor</italic>; <sup>24</sup>
<italic>AAAS</italic>: <italic>AAAS</italic> GENE; <sup>25</sup>
<italic>AIRE</italic>: <italic>autoimmune regulator.</italic>
</p></table-wrap-foot></table-wrap></p>
      <p>Replacement therapy with standard doses of glucocorticoid (hydrocortisone, 15&#xA0;mg/m<sup>2</sup>/day), mineralocorticoid (fluorocortisone, 0.2&#xA0;mg/day), and sodium chloride (NaCl, 1&#xA0;g/day) was initiated.</p>
      <p>Routine cytogenetic investigations revealed an apparently normal female karyotype (46, XX). Molecular karyotyping was performed using an array comparative genomic hybridization analysis using proband's DNA and a 44&#xA0;K array platform (Agilent Technologies) with a resolution of approximately 100 kilobase. This examination yielded normal results.</p>
      <p>After replacement therapy, electrolyte abnormalities were corrected during the first week, and the patient was discharged in good clinical condition. During follow-up, she maintained good condition, good appetite, weight gain, and normal laboratory results with reduced ACTH (Figure&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>). After 10&#xA0;days, ACTH was 3214&#xA0;ng/L; renin activity, 165.3 &#x3BC;U/mL; Na, 139&#xA0;mEq/L; K, 4.4&#xA0;mEq/L; and Cl, 96&#xA0;mEq/L, and after 40&#xA0;days ACTH was 797&#xA0;ng/L.<fig id="Fig2"><label>Figure 2</label><caption><p>
<bold>Corticotropin (ACTH) serum levels (ng/L) at diagnosis of adrenal insufficiency and the start of hydrocortisone (10&#xA0;months, 20&#xA0;days of age), after the start of macrogol (14 and 18&#xA0;months of age), and after the termination of macrogol (17 and 19&#xA0;months of age).</bold>
</p></caption><graphic xlink:href="13052_2014_78_Fig2_HTML" id="MO2"/></fig></p>
      <p>At 14&#xA0;months of age, the patient started taking macrogol twice daily for constipation, about 30 to 60&#xA0;minutes after taking hydrocortisone and fluorocortisone. Testing revealed that ACTH was 300&#xA0;ng/L, and renin activity was 24.2 &#x3BC;U/mL. Analysis of the <italic>SF1</italic> gene was normal with the exception of a c.437G&#x2009;&gt;&#x2009;C polymorphism.</p>
      <p>After 3&#xA0;months of macrogol therapy, Na was 135&#xA0;mEq/L; Cl, 106&#xA0;mEq/L; K, 5.3&#xA0;mEq/L; renin activity, 124.2 &#x3BC;U/mL; aldosterone, 0.13&#xA0;nmol/L; cortisol, 1.78&#xA0;&#x3BC;g/dL; and ACTH, 3262&#xA0;ng/L. The macrogol was stopped, resulting in a rapid reduction of corticotropin; after 28&#xA0;days it was 648&#xA0;ng/L. At this time, faecal elastase was 548&#xA0;&#x3BC;g/g (normal, &gt; 200&#xA0;&#x3BC;g/g), and steatocrit was 0% (normal, &lt; 3%). Screening for celiac disease was negative (IgA, 38&#xA0;mg/dL; tTG, 1.0 U/mL).</p>
      <p>Unfortunately, the family arbitrarily reintroduced macrogol (once daily, more than 2&#xA0;hours after taking hydrocortisone and fluorocortisone) for chronic constipation. After 1&#xA0;month, during a respiratory tract infection, the child presented with hypoglycaemia, lethargy, weakness, and hypotonia. Vitals were measured: pulse, 134/min; blood pressure, 65/42&#xA0;mm Hg; and respiration, 38/min. Glucose was 36&#xA0;mg/dL; Na, 132 nEq/L; Cl, 92&#xA0;mEq/L; K, 5.4&#xA0;mEq/L; and ACTH, 3145&#xA0;ng/L. During recovery, we treated the adrenal deficiency and stopped the macrogol with near normalization of corticotropin (323&#xA0;ng/L) after 23&#xA0;days (Figure&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>). Neuro-metabolic tests (plasma aminoacidogram, urine aminoacidogram, acylcarnitine profile analysis, and redox state) were again normal.</p>
    </sec>
    <sec id="Sec3" sec-type="discussion">
      <title>Discussion</title>
      <p>A variety of laxatives are available for treating constipation: bulk forming, osmotic, and stimulant laxatives. Osmotic laxatives, particularly PEG preparations, are popular because they are relatively safe, inexpensive, and better than lactulose in improving stool frequency and consistency [<xref ref-type="bibr" rid="CR12">12</xref>-<xref ref-type="bibr" rid="CR14">14</xref>]. Hydrocortisone is a hydrophilic drug used to treat many conditions, such as primary or secondary adrenal insufficiency, hypopituitarism, and adrenogenital syndrome.</p>
      <p>Nevertheless, treatment of children suffering from adrenal insufficiency is frequently problematic for a number of reasons. For example, it requires use of pharmaceutical formulations that do not fully address the pharmacokinetic and pharmacodynamic problems of dosing infants. Therefore, children require careful monitoring of dose and dosage regimen. In fact, patients with adrenal insufficiency continue to have increased mortality and morbidity despite treatment and monitoring [<xref ref-type="bibr" rid="CR15">15</xref>]. However, many drugs, for example, anticonvulsants such as phenytoin, phenobarbital, and carbamazepine, stimulate cytochrome P450 3A4, induce hepatic enzymes, and lead to accelerated glucocorticoid metabolism and reduced glucocorticoid effect, possibly causing acute adrenal insufficiency [<xref ref-type="bibr" rid="CR16">16</xref>].</p>
      <p>Hydrocortisone preparations are commonly combined with pharmaceutically acceptable carriers, typically inert, to facilitate their administration. Polyethylene glycol contains a mixture of inert water-soluble molecules of different sizes, whose absorption is independent of dosage, displaying decreasing mucosal transport with increasing molecular size. Macrogol solutions are commonly used for their efficacy and low rate of absorption (0.2%) after oral administration [<xref ref-type="bibr" rid="CR17">17</xref>] and typically have a safe profile with minimal reported side effects.</p>
      <p>A drug&#x2019;s solubility in water is an important factor influencing its release into the body. In addition, macrogol softens the faecal mass by osmotically drawing water into the GI tract. As our case showed, it is possible that macrogol reduces the absorption of hydrocortisone, facilitating the appearance of adrenal insufficiency. The case seems to support our hypothesis, considering the significant changes in corticotropin after starting and stopping macrogol. Furthermore, we could also speculate that the introduction of macrogol close to that of hydrocortisone or fluorocortisone could cause or contribute to the reduced absorption of these drugs, triggering the adrenal crisis. In fact, it is recognised that many physiological gastrointestinal factors may strongly influence the plasma concentration-time profile of hydrocortisone [<xref ref-type="bibr" rid="CR18">18</xref>]. However, hydrocortisone has a high permeability in both the small and large intestines, and the short elimination half-life (near 1.5&#xA0;h) requires two or more dose administrations per day [<xref ref-type="bibr" rid="CR18">18</xref>].</p>
      <p>This aspect is of great concern because patients with primary or secondary adrenal insufficiency have more than twofold increased mortality than the general population. However, recent data have demonstrated that the metabolic cardiovascular risk in hypopituitarism is related to the daily dose of hydrocortisone [<xref ref-type="bibr" rid="CR15">15</xref>].</p>
      <p>Our case report, while not demonstrating a genetic aetiology (polymorphism of <italic>SF1</italic> was the only abnormality), gives evidence of a possible genetic primary cause of adrenal insufficiency, based on clinical and laboratory examinations and the age of onset. In children, congenital primary adrenal insufficiency is very rare, accounting for about 1% of all cases. The importance of elucidating a genetic basis is emphasised by the ever-increasing number of genetic causes of adrenal insufficiency (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>) [<xref ref-type="bibr" rid="CR16">16</xref>]. In fact, in a series of 103 children with Addison&#x2019;s disease, genetic forms were very frequent, accounting for 72% of congenital adrenal hyperplasia; other genetic causes accounted for 6%, whereas autoimmune disease was diagnosed in only 13% [<xref ref-type="bibr" rid="CR19">19</xref>].</p>
      <p>As stressed by this case, prompt diagnosis is also important because acute adrenal insufficiency is a life threatening disease. Typically, patients with this disease present with severe hypotension to hypovolaemic shock, vomiting, acute abdominal pain, and often fever. However, children often present with hypoglycaemia and hypoglycaemic seizures. On the other hand, the primary non-specific symptoms of chronic adrenal insufficiency in children are fatigue, reduced muscle strength, weight loss, anorexia, or failure to thrive [<xref ref-type="bibr" rid="CR20">20</xref>].</p>
    </sec>
    <sec id="Sec4" sec-type="conclusion">
      <title>Conclusions</title>
      <p>This case report suggests that macrogol 3350 could interfere with the absorption of hydrocortisone. It is of particular importance considering the risk of adrenal insufficiency in these patients, and careful attention should be paid to the concomitant use of macrogol and hydrocortisone in subjects with primary or secondary glucocorticoid deficiencies.</p>
    </sec>
    <sec id="Sec5">
      <title>Consent</title>
      <p>Written informed consent was obtained from the parents of the patient for publication of this Case Report and any accompanying images.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn>
        <p>
          <bold>Competing interest</bold>
        </p>
        <p>The authors declare that there are no conflicts of interest that could be perceived as prejudicing the impartiality of the research reported.</p>
      </fn>
      <fn>
        <p>
          <bold>Authors&#x2019; contributions</bold>
        </p>
        <p>SStagi: conception and design, endocrinological evaluation, manuscript writing and final approval of the manuscript. FR: data collection and analysis, manuscript writing and final approval of the manuscript. PDG: data collection and analysis, manuscript writing and final approval of the manuscript. CI: endocrinological evaluation, data collection and analysis, manuscript writing and final approval of the manuscript. GP: data collection and analysis, critical revision and final approval of the manuscript. SSeminara: endocrinological evaluation, critical revision and final approval of the manuscript. MdM: critical revision and final approval of the manuscript. All authors read and approved the final manuscript.</p>
      </fn>
    </fn-group>
    <ack>
      <title>Acknowledgment</title>
      <p>We thank Prof. Paolo Lionetti for an invaluable help in revising our manuscript.</p>
      <sec id="FPar1">
        <title>Funding</title>
        <p>This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sectors.</p>
      </sec>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shulman</surname>
              <given-names>DI</given-names>
            </name>
            <name>
              <surname>Palmert</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Kemp</surname>
              <given-names>SF</given-names>
            </name>
            <collab>Lawson Wilkins Drug and Therapeutics Committee</collab>
          </person-group>
          <article-title>Adrenal insufficiency: still a cause of morbidity and death in childhood</article-title>
          <source>Pediatrics</source>
          <year>2007</year>
          <volume>119</volume>
          <fpage>e484</fpage>
          <lpage>e494</lpage>
          <pub-id pub-id-type="doi">10.1542/peds.2006-1612</pub-id>
          <pub-id pub-id-type="pmid">17242136</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Evliyao&#x11F;lu</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Dokurel</surname>
              <given-names>&#x130;</given-names>
            </name>
            <name>
              <surname>Bucak</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>&#xD6;zcab&#x131;</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Ercan</surname>
              <given-names>&#xD6;</given-names>
            </name>
            <name>
              <surname>Ceylaner</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Primary adrenal insufficiency caused by a novel mutation in DAX1 gene</article-title>
          <source>J Clin Res Pediatr Endocrinol</source>
          <year>2013</year>
          <volume>5</volume>
          <fpage>55</fpage>
          <lpage>57</lpage>
          <pub-id pub-id-type="doi">10.4274/Jcrpe.895</pub-id>
          <pub-id pub-id-type="pmid">23367499</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Charmandari</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Nicolaides</surname>
              <given-names>NC</given-names>
            </name>
            <name>
              <surname>Chrousos</surname>
              <given-names>GP</given-names>
            </name>
          </person-group>
          <article-title>Adrenal insufficiency</article-title>
          <source>Lancet</source>
          <year>2014</year>
          <volume>pii</volume>
          <fpage>S0140</fpage>
          <lpage>S6736</lpage>
          <pub-id pub-id-type="pmid">24503135</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Candy</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Belsey</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Macrogol (polyethylene glycol) laxatives in children with functional constipation and faecal impaction: a systematic review</article-title>
          <source>Arch Dis Child</source>
          <year>2009</year>
          <volume>94</volume>
          <fpage>156</fpage>
          <lpage>160</lpage>
          <pub-id pub-id-type="doi">10.1136/adc.2007.128769</pub-id>
          <pub-id pub-id-type="pmid">19019885</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Loening-Baucke</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <article-title>Prevalence, symptoms and outcome of constipation in infants and toddlers</article-title>
          <source>J Pediatr</source>
          <year>2005</year>
          <volume>146</volume>
          <fpage>359</fpage>
          <lpage>363</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jpeds.2004.10.046</pub-id>
          <pub-id pub-id-type="pmid">15756220</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sohy</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Vandenplus</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Sibille</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Usefulness of oral macrogol challenge in anaphylaxis after intra-articular injection of corticosteroid preparation</article-title>
          <source>Allergy</source>
          <year>2008</year>
          <volume>63</volume>
          <fpage>478</fpage>
          <lpage>479</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1398-9995.2007.01610.x</pub-id>
          <pub-id pub-id-type="pmid">18315736</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Napke</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Stevens</surname>
              <given-names>DGH</given-names>
            </name>
          </person-group>
          <article-title>Excipients and additives: hidden hazards in drug products and in product substitution</article-title>
          <source>CMAJ</source>
          <year>1984</year>
          <volume>131</volume>
          <fpage>1449</fpage>
          <lpage>1452</lpage>
          <pub-id pub-id-type="pmid">6498699</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bernier</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Donazzolo</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Effect of low-dose polyethylene glycol 4000 on fecal consistency and dilution water in healthy subjects</article-title>
          <source>Gastroent&#xE9;rol Clin Biol</source>
          <year>1997</year>
          <volume>21</volume>
          <fpage>7</fpage>
          <lpage>11</lpage>
          <pub-id pub-id-type="pmid">9091392</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schiller</surname>
              <given-names>LR</given-names>
            </name>
            <name>
              <surname>Emmett</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Santa Ana</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Fordtran</surname>
              <given-names>JS</given-names>
            </name>
          </person-group>
          <article-title>Osmotic effects of polyethylene glycol</article-title>
          <source>Gastroenterology</source>
          <year>1998</year>
          <volume>94</volume>
          <fpage>933</fpage>
          <lpage>941</lpage>
          <pub-id pub-id-type="pmid">3345895</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hammer</surname>
              <given-names>HF</given-names>
            </name>
            <name>
              <surname>Santa Ana</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Schiller</surname>
              <given-names>LR</given-names>
            </name>
            <name>
              <surname>Fordtran</surname>
              <given-names>JS</given-names>
            </name>
          </person-group>
          <article-title>Studies of osmotic diarrhea induced in normal subjects by ingestion of polyethylene glycol and lactulose</article-title>
          <source>J Clin Invest</source>
          <year>1989</year>
          <volume>84</volume>
          <fpage>1056</fpage>
          <lpage>1062</lpage>
          <pub-id pub-id-type="doi">10.1172/JCI114267</pub-id>
          <pub-id pub-id-type="pmid">2794043</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Corazziari</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Need of the ideal drug for the treatment of chronic constipation</article-title>
          <source>Ital J Gastroenterol Hepatol</source>
          <year>1999</year>
          <volume>31</volume>
          <issue>Suppl 3</issue>
          <fpage>S232</fpage>
          <lpage>S233</lpage>
          <pub-id pub-id-type="pmid">10726224</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Belsey</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Geraint</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Dixon</surname>
              <given-names>TA</given-names>
            </name>
          </person-group>
          <article-title>Systematic review and meta analysis: polyethylene glycol in adults with non-organic constipation</article-title>
          <source>Int J Clin Pract</source>
          <year>2010</year>
          <volume>64</volume>
          <fpage>944</fpage>
          <lpage>955</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1742-1241.2010.02397.x</pub-id>
          <pub-id pub-id-type="pmid">20584228</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Taylor</surname>
              <given-names>RR</given-names>
            </name>
            <name>
              <surname>Guest</surname>
              <given-names>JF</given-names>
            </name>
          </person-group>
          <article-title>The cost-effectiveness of macrogol 3350 compared to lactulose in the treatment of adults suffering from chronic constipation in the UK</article-title>
          <source>Aliment Pharmacol Ther</source>
          <year>2010</year>
          <volume>31</volume>
          <fpage>302</fpage>
          <lpage>312</lpage>
          <pub-id pub-id-type="pmid">19886948</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lee-Robichaud</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Thomas</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Morgan</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Nelson</surname>
              <given-names>RL</given-names>
            </name>
          </person-group>
          <article-title>Lactulose versus polyethylene glycol for chronic constipation</article-title>
          <source>Cochrane Database Syst Rev</source>
          <year>2010</year>
          <volume>7</volume>
          <pub-id pub-id-type="pmid">20614462</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Grossman</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Johannsson</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Quinkler</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Zelissen</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Therapy of endocrine disease: Perspectives on the management of adrenal insufficiency: clinical insights from across Europe</article-title>
          <source>Eur J Endocrinol</source>
          <year>2013</year>
          <volume>169</volume>
          <fpage>T165</fpage>
          <lpage>T175</lpage>
          <pub-id pub-id-type="doi">10.1530/EJE-13-0450</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Charmandari</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Nicolaides</surname>
              <given-names>NC</given-names>
            </name>
            <name>
              <surname>Chrousos</surname>
              <given-names>GP</given-names>
            </name>
          </person-group>
          <article-title>Adrenal insufficiency</article-title>
          <source>The Lancet</source>
          <year>2014</year>
          <volume>383</volume>
          <fpage>2152</fpage>
          <lpage>2167</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(13)61684-0</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tooson</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Gates</surname>
              <given-names>LK</given-names>
              <suffix>Jr</suffix>
            </name>
          </person-group>
          <article-title>Bowel preparation before colonoscopy. Choosing the best lavage regimen</article-title>
          <source>Postgrad Med</source>
          <year>1996</year>
          <volume>100</volume>
          <fpage>203</fpage>
          <lpage>214</lpage>
          <pub-id pub-id-type="pmid">8700818</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lennern&#xE4;s</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Skrtic</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Johannsson</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Replacement therapy of oral hydrocortisone in adrenal insufficiency: the influence of gastrointestinal factors</article-title>
          <source>Expert Opin Drug Metab Toxicol</source>
          <year>2008</year>
          <volume>4</volume>
          <fpage>749</fpage>
          <lpage>758</lpage>
          <pub-id pub-id-type="doi">10.1517/17425255.4.6.749</pub-id>
          <pub-id pub-id-type="pmid">18611115</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Perry</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Kecha</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Paquette</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Huot</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Van Vliet</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Deal</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Primary adrenal insufficiency in children: twenty years experience at the Sainte-Justine Hospital, Montreal</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2005</year>
          <volume>90</volume>
          <fpage>3243</fpage>
          <lpage>3250</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.2004-0016</pub-id>
          <pub-id pub-id-type="pmid">15811934</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Avgerinos</surname>
              <given-names>PC</given-names>
            </name>
            <name>
              <surname>Cutler</surname>
              <given-names>GB</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Tsokos</surname>
              <given-names>GC</given-names>
            </name>
            <name>
              <surname>Gold</surname>
              <given-names>PW</given-names>
            </name>
            <name>
              <surname>Feuillan</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Gallucci</surname>
              <given-names>WT</given-names>
            </name>
            <name>
              <surname>Pillemer</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Loriaux</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Chrousos</surname>
              <given-names>GP</given-names>
            </name>
          </person-group>
          <article-title>Dissociation between cortisol and adrenal androgen secretion in patients receiving alternate day prednisone therapy</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>1987</year>
          <volume>65</volume>
          <fpage>24</fpage>
          <lpage>29</lpage>
          <pub-id pub-id-type="doi">10.1210/jcem-65-1-24</pub-id>
          <pub-id pub-id-type="pmid">3034956</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
